PDIA5 and central nervous system cancer: Among pan-glioma, LGG, and GBM in the TCGA dataset, patients with higher PDIA5 levels presented shorter OS (Figure 2I), DSS (Supplementary Figure S2G), and PFI (Supplementary Figure S2H) compared to patients expressing low levels of PDIA5, with the exception of GBM which was not statistically significant for OS.